Abstract
Until recently, the mammalian tachykinins included substance P, neurokinin A and neurokinin B. Following the discovery of the fourth member of this family, hemokinin 1, a diverse group of novel tachykinins and tachykinin gene-related peptides have been identified in mammals. These newly identified members are preferentially expressed in peripheral tissues. Currently, the impact of these new tachykinin peptides on the immune system remains unclear. Some data imply an important role for hemokinin 1 in the generation of lymphocytes. Tachykinins are traditionally viewed as neuropeptides with well-defined functions as neurotransmitters. Many studies however, indicate that they may also be produced by non-neuronal cells, and exert profound influence on inflammatory responses by affecting multiple aspects of immune cell function. It is of great importance to determine whether the new tachykinin peptides have similar effects. A more detailed understanding of the interactions between tachykinins and immune cells may provide the basis for the development of new therapies for inflammatory and immune-mediated diseases.
Keywords: Tachykinin, Substance P, Hemokinin 1, Endokinin, Hematopoiesis, Lymphopoiesis, Immune cells
Current Drug Targets
Title: Tachykinins in the Immune System
Volume: 7 Issue: 8
Author(s): Yu Zhang, Alexandra Berger, Craig D. Milne and Christopher J. Paige
Affiliation:
Keywords: Tachykinin, Substance P, Hemokinin 1, Endokinin, Hematopoiesis, Lymphopoiesis, Immune cells
Abstract: Until recently, the mammalian tachykinins included substance P, neurokinin A and neurokinin B. Following the discovery of the fourth member of this family, hemokinin 1, a diverse group of novel tachykinins and tachykinin gene-related peptides have been identified in mammals. These newly identified members are preferentially expressed in peripheral tissues. Currently, the impact of these new tachykinin peptides on the immune system remains unclear. Some data imply an important role for hemokinin 1 in the generation of lymphocytes. Tachykinins are traditionally viewed as neuropeptides with well-defined functions as neurotransmitters. Many studies however, indicate that they may also be produced by non-neuronal cells, and exert profound influence on inflammatory responses by affecting multiple aspects of immune cell function. It is of great importance to determine whether the new tachykinin peptides have similar effects. A more detailed understanding of the interactions between tachykinins and immune cells may provide the basis for the development of new therapies for inflammatory and immune-mediated diseases.
Export Options
About this article
Cite this article as:
Zhang Yu, Berger Alexandra, Milne D. Craig and Paige J. Christopher, Tachykinins in the Immune System, Current Drug Targets 2006; 7 (8) . https://dx.doi.org/10.2174/138945006778019363
DOI https://dx.doi.org/10.2174/138945006778019363 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of T Cell Signaling and Function by Cbl-b
Current Immunology Reviews (Discontinued) Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression
Current Radiopharmaceuticals Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry What is the Best Option to Cure Patients with Resistant/Relapsing Hodgkins Disease?
Current Stem Cell Research & Therapy New Approaches to Mechanism Analysis for Drug Discovery Using DNA Microarray Data Combined with KeyMolnet
Current Drug Discovery Technologies An Update on Herbal Anti-inflammatory Agents in Periodontal Therapy
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors
Current Topics in Medicinal Chemistry Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry The Quinolone Family: From Antibacterial to Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Effect of Human Umbilical Cord Blood Progenitor Cells Versus Mononuclear Cells on Acute Renal Failure Rat Model
Current Stem Cell Research & Therapy Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry